About Us

Equillium is a clinical-stage biopharmaceutical company developing novel immune-modifying therapies for severe immuno-inflammatory diseases. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. Itolizumab has potential to be a best-in-class disease-modifying therapeutic and is currently being evaluated in clinical trials in multiple indications, including acute graft-versus-host disease, uncontrolled asthma, and SLE / lupus nephritis.

Executive Team

Board of Directors

Scientific and Clinical Advisors

Partners

Equillium acquired rights for developing and commercializing itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.